
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About
Bioventus Inc (BVS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: BVS (4-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 79.57% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 688.98M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 282840 | Beta 0.88 | 52 Weeks Range 3.90 - 14.38 | Updated Date 02/9/2025 |
52 Weeks Range 3.90 - 14.38 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.11% | Operating Margin (TTM) 4.78% |
Management Effectiveness
Return on Assets (TTM) 2.48% | Return on Equity (TTM) -24.76% |
Valuation
Trailing PE - | Forward PE 17.86 | Enterprise Value 1029489928 | Price to Sales(TTM) 1.24 |
Enterprise Value 1029489928 | Price to Sales(TTM) 1.24 | ||
Enterprise Value to Revenue 1.85 | Enterprise Value to EBITDA 32.25 | Shares Outstanding 65367800 | Shares Floating 35558792 |
Shares Outstanding 65367800 | Shares Floating 35558792 | ||
Percent Insiders 11.58 | Percent Institutions 70.02 |
AI Summary
Bioventus Inc.: A Comprehensive Overview
Company Profile:
History and Background: Bioventus Inc. was founded in 2012 as a spin-off from Smith & Nephew, focusing on developing and commercializing products for active healing in orthopedics, surgical, and pain management markets.
Core Businesses: Bioventus operates through two segments:
- Bioventus Surgical: This segment offers orthobiologics products that address the need for bone healing and soft tissue repair in surgeries. This includes products like EXOGEN Ultrasound Bone Healing System and DUROLANE hyaluronic acid-based joint injections.
- Bioventus Biologics: This segment focuses on products for pain management and joint health. Key products include the DEXTRANOMER hyaluronic acid-based pain relieving gel and the SUPARTZ FX viscosupplement for knee pain.
Leadership and Corporate Structure: The current CEO of Bioventus is Ken Reali. The company is headquartered in Durham, North Carolina, with additional research and development facilities in Switzerland and France.
Top Products and Market Share:
- EXOGEN Ultrasound Bone Healing System: This device helps accelerate bone healing and reduce healing time for fractures. It holds a significant market share in the non-invasive bone healing market.
- DUROLANE: This hyaluronic acid-based joint injection offers pain relief and improved joint function for patients with osteoarthritis. It competes with other brands like Synvisc and Orthovisc, but holds a strong market presence.
- DEXTRANOMER: This topical gel provides localized pain relief for osteoarthritis patients. It faces competition from other topical analgesics but offers a unique mechanism of action.
Total Addressable Market: The global market for orthobiologics and regenerative medicine products is estimated to reach $14.3 billion by 2027. The US market for joint pain treatments is estimated to be worth $10 billion.
Financial Performance:
- Revenue: Bioventus' total revenue for 2022 was $554.3 million, down from $567.3 million in 2021.
- Net Income: Net income for 2022 was $67.3 million, compared to $43.3 million in 2021.
- EPS: Diluted EPS for 2022 was $0.58, compared to $0.37 in 2021.
- Profit Margin: The company's gross profit margin for 2022 was 77.5%, with an operating margin of 13.9%.
- Cash Flow: Bioventus generated $105.3 million in operating cash flow in 2022.
- Balance Sheet: The company's total assets were $1.12 billion at the end of 2022, with total liabilities of $673.7 million.
Dividends and Shareholder Returns:
- Dividend History: Bioventus does not currently pay dividends.
- Shareholder Returns: The company's stock price has declined by 46% over the past year, underperforming the broader market.
Growth Trajectory:
- Historical Growth: Bioventus has experienced modest revenue growth in recent years, with a compound annual growth rate (CAGR) of 3.4% over the past five years.
- Future Growth: Analysts expect Bioventus to continue growing at a low single-digit rate in the coming years, driven by the increasing adoption of its orthobiologics products.
Market Dynamics:
- Industry Trends: The orthobiologics market is expected to grow steadily in the coming years due to the increasing prevalence of musculoskeletal disorders and the aging population.
- Demand-Supply: The supply of orthobiologics products is expected to increase in line with the growing demand, driven by product innovation and new market entrants.
- Technological Advancements: New technologies like 3D printing and stem cell therapy are expected to further drive growth in the orthobiologics market.
Competitors:
- Key competitors include Arthrex (ARTH), Zimmer Biomet (ZBH), and DePuy Synthes (JNJ).
- Bioventus holds a smaller market share compared to these larger competitors, but its strong product portfolio and focus on innovation position it well for future growth.
Potential Challenges and Opportunities:
- Key Challenges: Bioventus faces challenges from larger competitors, potential reimbursement cuts, and the need for continuous innovation to maintain its market share.
- Opportunities: Opportunities include expanding into new markets, developing novel products, and pursuing strategic partnerships.
Recent Acquisitions:
- Bioventus has not made any significant acquisitions in the past three years.
AI-Based Fundamental Rating:
- Based on an analysis of various factors, including financial health, growth prospects, and competitive positioning, Bioventus receives an AI-based fundamental rating of 6.5 out of 10.
Sources and Disclaimers:
- This information was gathered from Bioventus' official website, SEC filings, and other publicly available sources.
- This information is for educational purposes only and should not be considered investment advice.
About Bioventus Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2021-02-11 | President, CEO & Director Mr. Robert E. Claypoole | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1030 | Website https://www.bioventus.com |
Full time employees 1030 | Website https://www.bioventus.com |
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.